Jasper Huels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jasper Huels has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Lang
Market Access, Novartis Sverige AB, Kista, Sweden
1 shared publication - Andriy Danyliv
Novartis Ireland Limited, Dublin, Ireland.
1 shared publication - Farooq Maniyar
Basildon and Thurrock University Hospitals and Queen Mary University, London, UK
1 shared publication G. J. Hill
OptumInsight, Cambridge, MA,USA
1 shared publicationJ. Wassil
Novartis Vaccines and Diagnostics Inc.,Cambridge, MA,USA
1 shared publicationK. M. Clements
OptumInsight, Cambridge, MA,USA
1 shared publication
Latest Publications
- 25 January 2021
- Published by Springer Nature in PharmacoEconomics
- Vol. 39 (3) , 357-372
Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden
Background Migraine is a common neurological disease that disproportionately affects females and has a peak incidence during productive years, resulting in significant burden. Objective The aim of the study was to determine the cost effectiveness of erenumab for the preventive treatment of migraine. Methods A hybrid decision-tree plus Markov model was developed to evaluate the cost effectiveness of erenumab as a migraine treatment compared with best supportive care only for patients experiencing at least 4 monthly migraine days for whom at least two prior preventive treatments had failed. Clinical efficacy data were based on results from four randomized controlled trials of erenumab against placebo. The primary outcomes were costs, migraine days, and quality-adjusted life-years (QALYs). An incremental cost-effectiveness ratio (ICER) was estimated as the cost per QALY gained. The cost per migraine day avoided was also estimated, as were disaggregated direct and indirect costs. The analysis was conducted from Swedish societal and healthcare system perspectives based on total migraine, chronic migraine and episodic migraine populations, using a discount rate of 3% applied to both costs and health benefits and using year 2019 values. Results In the base-case deterministic analyses, erenumab treatment resulted in ICERs of Swedish krona (SEK) 34,696 (€3310) and SEK301,565 (€28,769) per QALY gained in the total migraine and episodic migraine populations, respectively. Erenumab was dominant in the chronic migraine population. In the total migraine population, the use of erenumab resulted in a net benefit to society of SEK81,739 (€7773) per patient, assuming a willingness-to-pay threshold of SEK300,000 (€28,528) per QALY. Conclusions Our analysis suggests that erenumab is a cost-effective treatment for migraine with a willingness-to-pay threshold of SEK300,000 per QALY.
- 25 January 2021
- Published by Springer Nature in PharmacoEconomics
- Vol. 39 (3) , 357-372
Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden
Background Migraine is a common neurological disease that disproportionately affects females and has a peak incidence during productive years, resulting in significant burden. Objective The aim of the study was to determine the cost effectiveness of erenumab for the preventive treatment of migraine. Methods A hybrid decision-tree plus Markov model was developed to evaluate the cost effectiveness of erenumab as a migraine treatment compared with best supportive care only for patients experiencing at least 4 monthly migraine days for whom at least two prior preventive treatments had failed. Clinical efficacy data were based on results from four randomized controlled trials of erenumab against placebo. The primary outcomes were costs, migraine days, and quality-adjusted life-years (QALYs). An incremental cost-effectiveness ratio (ICER) was estimated as the cost per QALY gained. The cost per migraine day avoided was also estimated, as were disaggregated direct and indirect costs. The analysis was conducted from Swedish societal and healthcare system perspectives based on total migraine, chronic migraine and episodic migraine populations, using a discount rate of 3% applied to both costs and health benefits and using year 2019 values. Results In the base-case deterministic analyses, erenumab treatment resulted in ICERs of Swedish krona (SEK) 34,696 (€3310) and SEK301,565 (€28,769) per QALY gained in the total migraine and episodic migraine populations, respectively. Erenumab was dominant in the chronic migraine population. In the total migraine population, the use of erenumab resulted in a net benefit to society of SEK81,739 (€7773) per patient, assuming a willingness-to-pay threshold of SEK300,000 (€28,528) per QALY. Conclusions Our analysis suggests that erenumab is a cost-effective treatment for migraine with a willingness-to-pay threshold of SEK300,000 per QALY.
- 28 November 2013
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 142 (9) , 2000-2012
Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK
SUMMARY: Neisseria meningitidis is the main cause of bacterial meningitis and sepsis in the UK, and can potentially be lethal or cause long-term sequelae. Bexsero® (4CMenB) is a new multi-component vaccine approved by the European Commission for use in individuals aged ⩾2 months. A theoretical transmission model was constructed to assess the long-term effectiveness of Bexsero compared to standard care. The model was populated with UK-specific demographic data and calibrated to ensure that the transmission dynamics of meningococcal disease in the UK were adequately simulated. The model showed the best strategy to be a routine vaccination programme at ages 2, 3, 4, 12 months and 14 years combined with a 5-year catch-up programme in toddlers aged 12–24 months and adolescents aged 15–18 years. This would lead to a 94% reduction in meningococcal cases or 150 000 cases and 15 000 deaths over a 100-year time-frame.
- 28 November 2013
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 142 (9) , 2000-2012
Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK
SUMMARY: Neisseria meningitidis is the main cause of bacterial meningitis and sepsis in the UK, and can potentially be lethal or cause long-term sequelae. Bexsero® (4CMenB) is a new multi-component vaccine approved by the European Commission for use in individuals aged ⩾2 months. A theoretical transmission model was constructed to assess the long-term effectiveness of Bexsero compared to standard care. The model was populated with UK-specific demographic data and calibrated to ensure that the transmission dynamics of meningococcal disease in the UK were adequately simulated. The model showed the best strategy to be a routine vaccination programme at ages 2, 3, 4, 12 months and 14 years combined with a 5-year catch-up programme in toddlers aged 12–24 months and adolescents aged 15–18 years. This would lead to a 94% reduction in meningococcal cases or 150 000 cases and 15 000 deaths over a 100-year time-frame.
- Open Access
- 1 January 2013
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 11 (1) , 23
Drug versus vaccine investment: a modelled comparison of economic incentives
Investment by manufacturers in research and development of vaccines is relatively low compared with that of pharmaceuticals. If current evaluation technologies favour drugs over vaccines, then the vaccines market becomes relatively less attractive to manufacturers.
- 1 January 2013
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 11 (1) , 23
Open AccessDrug versus vaccine investment: a modelled comparison of economic incentives
Investment by manufacturers in research and development of vaccines is relatively low compared with that of pharmaceuticals. If current evaluation technologies favour drugs over vaccines, then the vaccines market becomes relatively less attractive to manufacturers.